• Je něco špatně v tomto záznamu ?

Can Maternal Autoantibodies Play an Etiological Role in ASD Development?

I. Dudova, K. Horackova, M. Hrdlicka, M. Balastik,

. 2020 ; 16 (-) : 1391-1398. [pub] 20200603

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20019099

Autism spectrum disorder (ASD) is a heterogeneous condition with multiple etiologies and risk factors - both genetic and environmental. Recent data demonstrate that the immune system plays an important role in prenatal brain development. Deregulation of the immune system during embryonic development can lead to neurodevelopmental changes resulting in ASD. One of the potential etiologic factors in the development of ASD has been identified as the presence of maternal autoantibodies targeting fetal brain proteins. The type of ASD associated with the presence of maternal autoantibodies has been referred to as maternal antibodies related to ASD (MAR ASD). The link between maternal autoantibodies and ASD has been demonstrated in both clinical studies and animal models, but the exact mechanism of their action in the pathogenesis of ASD has not been clarified yet. Several protein targets of ASD-related maternal autoantibodies have been identified. Here, we discuss the role of microtubule-associated proteins of the collapsin response mediator protein (CRMP) family in neurodevelopment and ASD. CRMPs have been shown to integrate multiple signaling cascades regulating neuron growth, guidance or migration. Their targeting by maternal autoantibodies could change CRMP levels or distribution in the developing nervous system, leading to defects in axon growth/guidance, cortical migration, or dendritic projection, which could play an etiological role in ASD development. In addition, we discuss the future possibilities of MAR ASD treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019099
003      
CZ-PrNML
005      
20201123124126.0
007      
ta
008      
201103s2020 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/NDT.S239504 $2 doi
035    __
$a (PubMed)32581542
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Dudova, Iva $u Department of Child Psychiatry, Charles University Second Faculty of Medicine, Prague, Czech Republic.
245    10
$a Can Maternal Autoantibodies Play an Etiological Role in ASD Development? / $c I. Dudova, K. Horackova, M. Hrdlicka, M. Balastik,
520    9_
$a Autism spectrum disorder (ASD) is a heterogeneous condition with multiple etiologies and risk factors - both genetic and environmental. Recent data demonstrate that the immune system plays an important role in prenatal brain development. Deregulation of the immune system during embryonic development can lead to neurodevelopmental changes resulting in ASD. One of the potential etiologic factors in the development of ASD has been identified as the presence of maternal autoantibodies targeting fetal brain proteins. The type of ASD associated with the presence of maternal autoantibodies has been referred to as maternal antibodies related to ASD (MAR ASD). The link between maternal autoantibodies and ASD has been demonstrated in both clinical studies and animal models, but the exact mechanism of their action in the pathogenesis of ASD has not been clarified yet. Several protein targets of ASD-related maternal autoantibodies have been identified. Here, we discuss the role of microtubule-associated proteins of the collapsin response mediator protein (CRMP) family in neurodevelopment and ASD. CRMPs have been shown to integrate multiple signaling cascades regulating neuron growth, guidance or migration. Their targeting by maternal autoantibodies could change CRMP levels or distribution in the developing nervous system, leading to defects in axon growth/guidance, cortical migration, or dendritic projection, which could play an etiological role in ASD development. In addition, we discuss the future possibilities of MAR ASD treatment.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Horackova, Klara $u Department of Psychiatry, Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Hrdlicka, Michal $u Department of Child Psychiatry, Charles University Second Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Balastik, Martin $u Laboratory of Molecular Neurobiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.
773    0_
$w MED00183034 $t Neuropsychiatric disease and treatment $x 1176-6328 $g Roč. 16, č. - (2020), s. 1391-1398
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32581542 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123124125 $b ABA008
999    __
$a ind $b bmc $g 1585879 $s 1109297
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 16 $c - $d 1391-1398 $e 20200603 $i 1176-6328 $m Neuropsychiatric disease and treatment $n Neuropsychiatr Dis Treat $x MED00183034
LZP    __
$a Pubmed-20201103

Najít záznam

Citační ukazatele

Možnosti archivace